KR920009734B1 - 광견병 바이러스의 정제방법 - Google Patents
광견병 바이러스의 정제방법 Download PDFInfo
- Publication number
- KR920009734B1 KR920009734B1 KR1019850005785A KR850005785A KR920009734B1 KR 920009734 B1 KR920009734 B1 KR 920009734B1 KR 1019850005785 A KR1019850005785 A KR 1019850005785A KR 850005785 A KR850005785 A KR 850005785A KR 920009734 B1 KR920009734 B1 KR 920009734B1
- Authority
- KR
- South Korea
- Prior art keywords
- rabies virus
- cellulose
- virus
- solution
- sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241000711798 Rabies lyssavirus Species 0.000 title claims description 46
- 238000000034 method Methods 0.000 title claims description 23
- 238000000746 purification Methods 0.000 title claims description 8
- 229920002678 cellulose Polymers 0.000 claims description 23
- 239000001913 cellulose Substances 0.000 claims description 22
- 150000004676 glycans Chemical class 0.000 claims description 16
- 229920001282 polysaccharide Polymers 0.000 claims description 16
- 239000005017 polysaccharide Substances 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 13
- -1 sulfuric acid ester Chemical class 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 5
- 210000003837 chick embryo Anatomy 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 4
- 230000001902 propagating effect Effects 0.000 claims description 4
- 229920000936 Agarose Polymers 0.000 claims description 3
- 239000001963 growth medium Substances 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 1
- 239000000243 solution Substances 0.000 description 25
- 235000010980 cellulose Nutrition 0.000 description 18
- 239000000499 gel Substances 0.000 description 11
- 206010037742 Rabies Diseases 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000001993 wax Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229960002086 dextran Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- XZEUAXYWNKYKPL-URLMMPGGSA-N ormeloxifene Chemical compound C1([C@@H]2[C@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-URLMMPGGSA-N 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- DEWLEGDTCGBNGU-UHFFFAOYSA-N 1,3-dichloropropan-2-ol Chemical compound ClCC(O)CCl DEWLEGDTCGBNGU-UHFFFAOYSA-N 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000428199 Mustelinae Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000001180 sulfating effect Effects 0.000 description 1
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Inorganic materials O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20151—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Filtering Of Dispersed Particles In Gases (AREA)
- Activated Sludge Processes (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP168226 | 1984-08-10 | ||
| JP59168226A JPS6147187A (ja) | 1984-08-10 | 1984-08-10 | 狂犬病ウイルスの精製方法 |
| JP59-168226 | 1984-08-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR870001836A KR870001836A (ko) | 1987-03-28 |
| KR920009734B1 true KR920009734B1 (ko) | 1992-10-22 |
Family
ID=15864114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019850005785A Expired KR920009734B1 (ko) | 1984-08-10 | 1985-08-10 | 광견병 바이러스의 정제방법 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4725547A (cg-RX-API-DMAC10.html) |
| EP (1) | EP0171771B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JPS6147187A (cg-RX-API-DMAC10.html) |
| KR (1) | KR920009734B1 (cg-RX-API-DMAC10.html) |
| AT (1) | ATE50594T1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA1251398A (cg-RX-API-DMAC10.html) |
| DE (1) | DE3576172D1 (cg-RX-API-DMAC10.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5447859A (en) * | 1993-07-16 | 1995-09-05 | Viagene | Method for the purification or removal of retroviruses using sulfated cellulose |
| US7732129B1 (en) * | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| EP0968284B1 (en) * | 1996-11-20 | 2006-12-13 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| JP2002142770A (ja) | 2000-11-08 | 2002-05-21 | Dnavec Research Inc | 循環系への遺伝子送達用パラミクソウイルスベクター |
| PL354822A1 (en) * | 2002-06-30 | 2004-01-12 | Instytut Immunologii i Terapii Doświadczalnej PANwe Wrocławiu | Method of receiving purified bacteriophage preparations and new applications of polysaccharide or its esterificated derivative |
| CA2529053A1 (en) * | 2003-06-18 | 2004-12-29 | Onyx Pharmaceuticals, Inc. | Method for purifying virus |
| KR101279748B1 (ko) | 2003-11-04 | 2013-07-04 | 가부시키가이샤 디나벡크 겐큐쇼 | 유전자 도입된 수상세포의 제조방법 |
| CN101080488A (zh) * | 2004-11-03 | 2007-11-28 | 因特罗根治疗公司 | 生产和纯化腺病毒载体的新方法 |
| JP4969444B2 (ja) | 2005-06-14 | 2012-07-04 | ディナベック株式会社 | 抗体の作製方法 |
| US20100167341A1 (en) | 2006-01-17 | 2010-07-01 | Dnavec Corporation | Novel protein expression system |
| CA2658266A1 (en) | 2006-07-13 | 2008-01-17 | Dnavec Corporation | Non-replicating paramyxoviridae virus vector |
| EP2143794A1 (en) | 2007-04-27 | 2010-01-13 | Kyushu University, National University Corporation | Viral vector for gene therapy |
| FR2944292B1 (fr) * | 2009-04-08 | 2013-08-23 | Sanofi Pasteur | Procede de purification du virus rabique |
| SG184833A1 (en) | 2010-04-14 | 2012-11-29 | Emd Millipore Corp | Methods of producing high titer, high purity virus stocks and methods of use thereof |
| DE102013017014B4 (de) | 2013-10-14 | 2017-03-30 | Sartorius Stedim Biotech Gmbh | Sulfatierte Cellulosehydrat-Membran, Verfahren zur ihrer Herstellung und Verwendung der Membran als Adsorptionsmembran für die Virenaufreinigung |
| ES2975182T3 (es) | 2017-03-06 | 2024-07-03 | Guangzhou Realbenefitspot Pharmaceutical Co Ltd | Métodos de producción y caracterización de vacunas víricas y composición de vacuna vírica |
| EP3420076B1 (en) * | 2017-03-06 | 2024-02-21 | Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. | Methods of producing and characterizing virus vaccine and virus vaccine composition |
| CN108993456B (zh) * | 2018-07-26 | 2021-02-26 | 武汉汇研生物科技股份有限公司 | 一种狂犬病毒吸附层析介质及其制备方法 |
| CN113607838A (zh) * | 2021-07-29 | 2021-11-05 | 长春卓谊生物股份有限公司 | 一种β-丙內酯残留量检测方法及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL131092C (cg-RX-API-DMAC10.html) * | ||||
| US3105012A (en) * | 1961-10-19 | 1963-09-24 | Parke Davis & Co | Antigen products and means for producing the same |
| SE356735B (cg-RX-API-DMAC10.html) * | 1970-12-02 | 1973-06-04 | Svenska Cellulosa Ab | |
| US3973000A (en) * | 1972-02-04 | 1976-08-03 | Eli Lilly And Company | Process for purified rabies vaccine |
| US3842062A (en) * | 1972-09-27 | 1974-10-15 | Du Pont | Water-soluble complexes of protein and anionic polyelectrolytes such as sodium carboxymethyl cellulose |
| US3920625A (en) * | 1973-06-19 | 1975-11-18 | Kabi Ab | Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates |
| US4160018A (en) * | 1973-06-25 | 1979-07-03 | Bjorklund Knut B | Stabilized cancer associated polypeptide antigen and preparation thereof |
| IL49752A (en) * | 1975-07-09 | 1979-07-25 | Kabi Ab | Compositions having affinity for hepatitis virus and method for hepatitis virus removal or concentration |
| SE420977B (sv) * | 1976-03-18 | 1981-11-16 | Kabi Ab | Forfarande for rening och isolering av hepatitvirus for vaccinframstellning |
| DE2616407C3 (de) * | 1976-04-14 | 1980-02-21 | Behringwerke Ag, 3550 Marburg | Verfahren zur Herstellung eines Tollwut-Impfstoffs |
| GB1596653A (en) * | 1977-01-26 | 1981-08-26 | Gist Brocades Nv | Vaccine |
| US4181713A (en) * | 1978-10-30 | 1980-01-01 | Merck & Co., Inc. | Isolation of HBs Ag |
| CH638985A5 (de) * | 1979-04-10 | 1983-10-31 | Schweiz Serum & Impfinst | Verfahren zur herstellung eines tollwutimpfstoffes und danach erhaltener impfstoff. |
| JPS57136528A (en) * | 1981-02-09 | 1982-08-23 | Hayashibara Biochem Lab Inc | Preparation of viral vaccine |
| US4434093A (en) * | 1982-07-26 | 1984-02-28 | Ortho Diagnostic Systems Inc. | Methods for preparation of HBs Ag free gamma globulins |
| US4515714A (en) * | 1983-03-09 | 1985-05-07 | Juridicial Foundation, The Chemo-Semo-Sero-Therapeutic Research Institute | Method for purification of hepatitis B virus surface antigen |
-
1984
- 1984-08-10 JP JP59168226A patent/JPS6147187A/ja active Granted
-
1985
- 1985-08-08 CA CA000488280A patent/CA1251398A/en not_active Expired
- 1985-08-09 EP EP85110047A patent/EP0171771B1/en not_active Expired - Lifetime
- 1985-08-09 US US06/764,132 patent/US4725547A/en not_active Expired - Lifetime
- 1985-08-09 DE DE8585110047T patent/DE3576172D1/de not_active Expired - Lifetime
- 1985-08-09 AT AT85110047T patent/ATE50594T1/de not_active IP Right Cessation
- 1985-08-10 KR KR1019850005785A patent/KR920009734B1/ko not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CA1251398A (en) | 1989-03-21 |
| EP0171771B1 (en) | 1990-02-28 |
| EP0171771A3 (en) | 1988-01-07 |
| KR870001836A (ko) | 1987-03-28 |
| EP0171771A2 (en) | 1986-02-19 |
| US4725547A (en) | 1988-02-16 |
| JPS6147187A (ja) | 1986-03-07 |
| JPS6230753B2 (cg-RX-API-DMAC10.html) | 1987-07-03 |
| DE3576172D1 (de) | 1990-04-05 |
| ATE50594T1 (de) | 1990-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR920009733B1 (ko) | 인플루엔자 바이러스의 정제방법 | |
| KR920009731B1 (ko) | 일본뇌염 바이러스의 정제방법 | |
| EP0171771B1 (en) | A method for purification of rabies virus | |
| SU1268105A3 (ru) | Композиционный материал дл анионообменника и способ его получени | |
| KR920009735B1 (ko) | 단순 헤르페스 바이러스 서브유니트 왁진의 제조방법 | |
| Lincoln | [8] cGMP-dependent protein kinase | |
| CA1216790A (en) | Method for purification of hepatitis b virus surface antigen | |
| JPS58201794A (ja) | ヒトインターフェロンβの濃縮精製法 | |
| EP0159003A2 (en) | Method for purification of filamentous hemagglutinin | |
| CN107051396A (zh) | 一种定点固定蛋白a的免疫吸附材料及其制备方法 | |
| JPH06128296A (ja) | ヒトアンチトロンビン−ｉｉｉの調製方法 | |
| JPH0423751B2 (cg-RX-API-DMAC10.html) | ||
| JPH0423752B2 (cg-RX-API-DMAC10.html) | ||
| Paschke et al. | Multiple forms of 2-deoxy-D-glucoside-2-sulphamate sulphohydrolase from human placenta | |
| Jansson et al. | Isolation and characterization of a 23 kDa protein essential for photosynthetic oxygen evolution | |
| EP0170162B1 (en) | Method for the purification of leukocytosis-promoting factor haemagglutinin | |
| JP2627186B2 (ja) | レトロウイルスの精製方法 | |
| JPS641446B2 (cg-RX-API-DMAC10.html) | ||
| JP6548293B2 (ja) | ｂＦＧＦの精製方法およびｂＦＧＦの製造方法 | |
| JPS632936B2 (cg-RX-API-DMAC10.html) | ||
| CA1076026A (en) | Method of isolating albumin from blood products | |
| JPH01272599A (ja) | 新規蛋白質ｂａｐ−２及びそれを含有する植物ウィルス病防除剤 | |
| PT95992A (pt) | Processo para a purificacao de lipocortinas | |
| GB2045257A (en) | Plasminogen-activating substance and its preparation and use | |
| JPS6363391A (ja) | 生理活性物質の製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19850810 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19900703 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19850810 Comment text: Patent Application |
|
| G160 | Decision to publish patent application | ||
| PG1605 | Publication of application before grant of patent |
Comment text: Decision on Publication of Application Patent event code: PG16051S01I Patent event date: 19920930 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 19930119 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 19930325 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 19930325 End annual number: 3 Start annual number: 1 |
|
| PR1001 | Payment of annual fee |
Payment date: 19951021 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 19961021 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 19970826 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 19980508 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 19990707 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20000713 Start annual number: 9 End annual number: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20010612 Start annual number: 10 End annual number: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20020709 Start annual number: 11 End annual number: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20030612 Start annual number: 12 End annual number: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20040629 Year of fee payment: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20040629 Start annual number: 13 End annual number: 13 |
|
| EXPY | Expiration of term | ||
| PC1801 | Expiration of term |